What's In The Cards For Agilent (A) In Q1 Earnings Season?
Zacks Investment Research | Feb 12, 2018 03:25AM ET
Agilent Technologies, Inc. (NYSE:A) is set to report first-quarter fiscal 2018 on Feb 14.
Notably, the company has beaten the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average positive surprise of 12.20%.
Last quarter, Agilent delivered a positive earnings surprise of 6.35%. Earnings of 67 cents increased 13.6% sequentially as well as year over year.
Revenues increased 8% sequentially and 7% year over year to $1.19 billion. Top line growth was driven by strength across all product lines, particularly in Europe and Americas.
For first-quarter fiscal 2018, Agilent expects revenues in the range of $1.145-1.165 billion. Non-GAAP earnings are expected between 55 cents and 57 cents per share.
Let’s see how things are shaping up for this announcement.
Expanding Product Portfolio
Agilent Technologies has shifted its focus to life sciences, genomics, diagnostics and wireless test markets, in which it has made a few important acquisitions and alliances.
Broad-based growth in all product lines is the driver for Agilent. We believe that the company’s continuous effort on expanding product portfolio and strategic acquisitions is likely to drive results in the soon-to-be-reported quarter.
In the first quarter fiscal 2018, Agilent completed the acquisition of Luxcel Biosciences, which expands its cell analysis portfolio. This acquisition brings in assay kits that are easy to use and compatible with industry-standard plate-readers. Hence, the deal is likely to benefit Agilent’s position in the pharmaceutical industry.
Further, the integration of U.K.-based Cobalt Light Systems will strengthen Agilent’s position in the high-growth Raman spectroscopy market.
Segment Estimates Positive
Life Sciences & Applied Markets Group (LSAG) revenues are expected to increase, driven by growing chemical, energy, pharma and food end markets. Revenues from this segment, as per the Zacks Consensus Estimate, are currently pegged at $578 million.
The consensus estimate for revenues for the Agilent Cross Lab Group (ACG) stands at $401 million.
Moreover, Diagnostics and Genomics Group (DGG) is likely to benefit from increasing demand for medical services and products. Revenues from this segment, as per the Zacks Consensus Estimate, are currently pegged at $181 million.
Agilent Technologies, Inc. Price and EPS Surprise
Agilent Technologies, Inc. Quote
What Our Model Suggests
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive the complete list of today’s Zacks #1 Rank stocks here .
Get The News You Want
HubSpot (NYSE:HUBS) has an Earnings ESP of +1.32% and a Zacks Rank #3.
Broadcom (NASDAQ:AVGO) has an Earnings ESP of +1.08% and a Zacks Rank #3.
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP, Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.